What is HC Wainwright’s Estimate for SABS Q3 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – HC Wainwright reduced their Q3 2026 EPS estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($0.60) EPS, FY2028 earnings at ($0.47) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.48) EPS.

Several other research firms have also issued reports on SABS. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Citigroup initiated coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Jefferies Financial Group started coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Down 0.5%

SABS stock opened at $3.76 on Monday. SAB Biotherapeutics has a 12 month low of $1.85 and a 12 month high of $5.15. The firm has a market cap of $342.12 million, a PE ratio of -2.89 and a beta of 0.53. The firm has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $3.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28).

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently made changes to their positions in SABS. Bank of New York Mellon Corp purchased a new stake in shares of SAB Biotherapeutics in the 2nd quarter valued at approximately $421,000. Seven Fleet Capital Management LP acquired a new stake in SAB Biotherapeutics during the 1st quarter valued at $1,915,000. DV Trading LLC acquired a new stake in SAB Biotherapeutics during the 1st quarter valued at $1,532,000. Perceptive Advisors LLC lifted its holdings in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of SAB Biotherapeutics by 424.8% in the first quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after purchasing an additional 45,084 shares in the last quarter. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.